MEDICAL DEVICE FOR CONTROLLED RELEASE OF DRUG

MEDICAL DEVICE FOR CONTROLLED RELEASE OF DRUG

The purpose of the present invention is to provide a medical device for the controlled release of a drug suitable for an ophthalmic lens that, compared to a conventional contact lens for controlled release of a drug, releases a reduced initial controlled longer-release amount of the drug retained in...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: SYOUJI KIYOSHI, MATSUNAGA TORU, YAMAZAKI KEIKO, SATO TAKAO
Format: Patent
Sprache:eng ; fre ; ger
Schlagworte:
BANDAGES, DRESSINGS OR ABSORBENT PADS
CONTACT LENSES
DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF,TUBULAR STRUCTURES OF THE BODY, E.G. STENTS
FILTERS IMPLANTABLE INTO BLOOD VESSELS
FIRST-AID KITS
FOMENTATION
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
OPTICAL ELEMENTS, SYSTEMS, OR APPARATUS
OPTICS
ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES
PHYSICS
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROSTHESES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
SPECTACLES
SUNGLASSES OR GOGGLES INSOFAR AS THEY HAVE THE SAME FEATURESAS SPECTACLES
TREATMENT OR PROTECTION OF EYES OR EARS
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The purpose of the present invention is to provide a medical device for the controlled release of a drug suitable for an ophthalmic lens that, compared to a conventional contact lens for controlled release of a drug, releases a reduced initial controlled longer-release amount of the drug retained in the device and as a result, thus enabling longer-term controlled release of the drug in a therapeutically effective dose, such device having the same oxygen permeability as that a conventional SHGCL. The foregoing is accomplished by a medical device for the controlled release of a drug comprising an amphiphilic hydrogel that retains a drug, where the rate of controlled release of the drug is 50 wt% or less 24 hours after drug release is initiated.